BR0207549A - Androgen receptor modulating tricyclic compounds and methods - Google Patents

Androgen receptor modulating tricyclic compounds and methods

Info

Publication number
BR0207549A
BR0207549A BR0207549-0A BR0207549A BR0207549A BR 0207549 A BR0207549 A BR 0207549A BR 0207549 A BR0207549 A BR 0207549A BR 0207549 A BR0207549 A BR 0207549A
Authority
BR
Brazil
Prior art keywords
methods
androgen receptor
receptor modulating
tricyclic compounds
compounds
Prior art date
Application number
BR0207549-0A
Other languages
Portuguese (pt)
Inventor
Lin Zhi
Cornelis Arjan Van Oeveren
Jyun-Hung Chen
Robert I Higuchi
Original Assignee
Ligand Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ligand Pharm Inc filed Critical Ligand Pharm Inc
Publication of BR0207549A publication Critical patent/BR0207549A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/16—Masculine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/08—Antiseborrheics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/26—Androgens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Reproductive Health (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Nutrition Science (AREA)
  • Gynecology & Obstetrics (AREA)
  • Rheumatology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Urology & Nephrology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Quinoline Compounds (AREA)

Abstract

"COMPOSTOS TRICìCLICOS MODULADORES DE RECEPTOR DE ANDROGêNIO E MéTODOS". A presente invenção refere-se aos compostos tricíclicos não-esteroidais que são moduladores de receptores de androgênio e aos métodos para produzir e usar tais compostos."TRICYCLIC ANDROGEN RECEPTOR MODULATING COMPOUNDS AND METHODS". The present invention relates to non-steroidal tricyclic compounds which are androgen receptor modulators and methods for producing and using such compounds.

BR0207549-0A 2001-02-23 2002-02-23 Androgen receptor modulating tricyclic compounds and methods BR0207549A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US27118901P 2001-02-23 2001-02-23
PCT/IB2002/000537 WO2002066475A2 (en) 2001-02-23 2002-02-23 Tricyclic androgen receptor modulator compounds

Publications (1)

Publication Number Publication Date
BR0207549A true BR0207549A (en) 2004-08-03

Family

ID=23034558

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0207549-0A BR0207549A (en) 2001-02-23 2002-02-23 Androgen receptor modulating tricyclic compounds and methods

Country Status (9)

Country Link
US (3) US7026484B2 (en)
EP (1) EP1363909B1 (en)
JP (3) JP4578053B2 (en)
CN (2) CN101215286A (en)
AU (1) AU2002236114A1 (en)
BR (1) BR0207549A (en)
CA (1) CA2434299C (en)
MX (1) MXPA03007421A (en)
WO (1) WO2002066475A2 (en)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CZ2002711A3 (en) * 1999-08-27 2003-11-12 Ligand Pharmaceuticals Incorporated Androgenic receptor modulators, process of their preparation and their use
US6566372B1 (en) 1999-08-27 2003-05-20 Ligand Pharmaceuticals Incorporated Bicyclic androgen and progesterone receptor modulator compounds and methods
US7026484B2 (en) * 2001-02-23 2006-04-11 Ligand Pharmaceuticals Incorporated Tricyclic androgen receptor modulator compounds and methods
US7214690B2 (en) * 2001-02-23 2007-05-08 Ligand Pharmaceuticals Incorporated Tricyclic quinolinone and tricyclic quinoline androgen receptor modulator compounds and methods
FR2825268B1 (en) 2001-05-31 2004-09-17 Oreal COSMETIC COMPOSITION COMPRISING CALCIUM CARBONATE PARTICLES AND CONDITIONERS
CA2463311A1 (en) * 2001-10-19 2003-05-01 Paul J. Coleman Androgen receptor modulators and methods of use thereof
EP1467730A4 (en) * 2002-01-22 2010-03-10 Univ California Non-steroidal ligands for the glucocorticoid receptor, compositions and uses thereof
WO2003090672A2 (en) * 2002-04-26 2003-11-06 Ortho-Mcneil Pharmaceutical, Inc. 2-(quinolonyl)-fused heterocycles as androgen receptor modulators
JPWO2004066994A1 (en) * 2003-01-28 2006-05-18 関西ティー・エル・オー株式会社 Anticancer drug
US7227023B2 (en) 2003-04-30 2007-06-05 Wyeth Quinoline 3-amino chroman derivatives
EP1656142A4 (en) * 2003-08-22 2011-06-22 Ligand Pharm Inc 6-cycloamino-2-quinolinone derivatives as androgen receptor modulator compounds
WO2005090282A1 (en) 2004-03-12 2005-09-29 Ligand Pharmaceuticals Incorporated Androgen receptor modulator compounds and methods
EP1817292B1 (en) * 2004-11-16 2015-04-08 Janssen Pharmaceutica NV Novel heterocycle derivatives useful as selective androgen receptor modulators (sarms)
CA2598216C (en) * 2005-06-17 2014-04-08 Ligand Pharmaceuticals Incorporated Androgen receptor modulator compounds and methods
EP1916896A4 (en) * 2005-08-26 2010-08-11 Univ California Non-steroidal antiandrogens
DE102006029445A1 (en) * 2006-06-21 2007-12-27 Bayer Schering Pharma Ag New 3-cyano-quinolines as kinase inhibitors
DE102006029446A1 (en) * 2006-06-21 2007-12-27 Bayer Schering Pharma Ag New 3-substituted quinolines as kinase inhibitors
US8189607B2 (en) * 2007-03-16 2012-05-29 Telefonaktiebolaget L M Ericsson (Publ) Interface selection in a moving network
CA2709677C (en) 2007-12-21 2017-03-14 Lin Zhi Selective androgen receptor modulators (sarms) and uses thereof
EP2130831A1 (en) 2008-06-06 2009-12-09 InterMed Discovery GmbH CDC25 inhibitors
CA2769512C (en) 2009-07-29 2019-07-09 Duke University Compositions comprising fp receptor antagonists and their use for inhibiting hair growth
CN103327977B (en) 2011-01-31 2016-05-04 东丽株式会社 Dyscrasic treatment or prophylactic
TWI537274B (en) * 2011-03-14 2016-06-11 橘生藥品工業股份有限公司 Novel octahydrothienoquinoline derivatives, pharmaceutical compositions containing the same, and their uses
CN106565734B (en) * 2016-11-09 2018-07-03 中国科学院新疆理化技术研究所 A kind of psoralen ester derivative and purposes
CN106543197B (en) * 2016-11-09 2018-07-20 中国科学院新疆理化技术研究所 A kind of psoralen Schiff bases derivative and purposes
US11420196B2 (en) 2018-09-27 2022-08-23 Chevron Phillips Chemical Company Lp Processes for producing fluorided solid oxides and uses thereof in metallocene-based catalyst systems
EP4049658A4 (en) 2019-10-24 2023-11-22 Toray Industries, Inc. Therapeutic or prophylactic agent for cachexia
TW202216145A (en) 2020-06-30 2022-05-01 日商東麗股份有限公司 Ameliorating agent or prophylactic agent for muscle weakness symptom in disease or syndrome associated with metabolic disorder

Family Cites Families (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2126811A1 (en) 1971-05-29 1972-12-14 Basf Ag Fluorescent pigments dyes - of the coumarin series for synthetic fibres and plastics
BE795696A (en) 1972-02-28 1973-08-21 Agfa Gevaert Nv FOR HEAT SENSITIVE MATERIALS
US3919238A (en) 1973-06-06 1975-11-11 Morton Norwich Products Inc 9-(Substituted amino)imidazo(4,5-f) quinolines
JPS5025595A (en) 1973-07-09 1975-03-18
SU548608A1 (en) * 1975-07-16 1977-02-28 Московский Ордена Ленина И Ордена Трудового Красного Знамени Государственный Университет Им.М.В.Ломоносова Method for preparing substituted pyrroquinolines
JPS58170506A (en) * 1982-03-30 1983-10-07 Sumitomo Chem Co Ltd Treatment of mutagenic substance
JPH0615036B2 (en) * 1984-03-27 1994-03-02 住友化学工業株式会社 Silica gel bonded with phthalocyanine and method for treating polycyclic organic substance using the same
US5071773A (en) * 1986-10-24 1991-12-10 The Salk Institute For Biological Studies Hormone receptor-related bioassays
US4777052A (en) * 1987-01-06 1988-10-11 American Health Foundation Method of treating a foodstuff to inhibit the development of mutagens and related product
US4981784A (en) * 1987-12-02 1991-01-01 The Salk Institute For Biological Studies Retinoic acid receptor method
WO1989007441A1 (en) 1988-02-10 1989-08-24 The Regents Of The University Of California 6-amino-1,2-benzopyrone antitumorigenic agents and method
WO1990008529A2 (en) * 1989-01-23 1990-08-09 Lehigh University 7-alkoxycoumarins, dihydropsoralens, and benzodipyranones as photo-activated therapeutic agents and inhibitors of epidermal growth factor
ES2061923T3 (en) * 1989-12-27 1994-12-16 Nestle Sa PROCEDURE FOR THE REACTION OF A GRAFTED DEXTRANOMER AND OF A PHTHALOCIANINIC DYE AND ITS USE.
JP3047434B2 (en) 1990-03-27 2000-05-29 株式会社トクヤマ Photochromic molding
CA2134448A1 (en) * 1992-05-01 1993-11-02 Yoshinori Kyotani Quinoline derivative or salt thereof and remedy for cardiac diseases containing the same
WO1994023068A1 (en) 1993-04-07 1994-10-13 Ligand Pharmaceuticals, Incorporated Method for screening for receptor agonists
JP2822848B2 (en) 1993-06-28 1998-11-11 株式会社ニコン Photochromic plastic lens and method of manufacturing the same
US5677336A (en) 1993-10-21 1997-10-14 Ligand Pharmaceuticals Incorporated Non-steroid androgen receptor antagonist compounds and methods
PT800519E (en) * 1994-12-22 2004-03-31 Ligand Pharm Inc STEROID RECEPTOR MODULATORS AND METHODS
US6696459B1 (en) 1994-12-22 2004-02-24 Ligand Pharmaceuticals Inc. Steroid receptor modulator compounds and methods
US5696130A (en) 1994-12-22 1997-12-09 Ligand Pharmaceuticals Incorporated Tricyclic steroid receptor modulator compounds and methods
ES2141978T3 (en) 1994-12-30 2000-04-01 Ligand Pharm Inc TRICYCLIC RETINOIDS, METHODS FOR THEIR PRODUCTION AND USE.
NZ304330A (en) * 1995-04-04 1999-05-28 Novartis Ag Cell growth substrate having at least one perfluorinated polyester, two polymerisable groups and a di-functional linking group
WO1996036230A1 (en) 1995-05-16 1996-11-21 The Salk Institute For Biological Studies Modulators for new members of the steroid/thyroid superfamily of receptors
AU6263996A (en) 1995-06-07 1996-12-30 Ligand Pharmaceuticals Incorporated Method for screening for receptor agonists and antagonists
DE69627193T2 (en) 1995-10-06 2004-01-29 Ligand Pharm Inc DIMER-SELECTIVE RXR MODULATORS AND METHOD FOR THEIR USE
DK0918774T3 (en) 1996-06-27 2002-05-21 Ligand Pharm Inc Androgen receptor modulator compounds and methods
US6017924A (en) * 1996-06-27 2000-01-25 Ligand Pharmaceuticals Incorporated Androgen receptor modulator compounds and methods
CA2259031C (en) 1996-06-27 2006-10-24 Ligand Pharmaceuticals Incorporated Androgen receptor modulator compounds and methods
ID18046A (en) * 1996-08-20 1998-02-19 Takeda Chemical Industries Ltd COMPOUND, MIXED CYCLE, MANUFACTURE AND USE OF IT.
EP0975621A1 (en) * 1997-04-25 2000-02-02 Takeda Chemical Industries, Ltd. Cell differentiation inducing amide derivatives, their production and use
JPH1129471A (en) * 1997-07-04 1999-02-02 Nippon Chemiphar Co Ltd Medicine containing cumarin-derivative as active ingredient for liver disease
US6506766B1 (en) 1998-02-13 2003-01-14 Abbott Laboratories Glucocortiocoid-selective antinflammatory agents
US6380207B2 (en) 1998-02-13 2002-04-30 Abbott Laboratories Glucocortiocoid-selective antiinflammatory agents
US6001846A (en) * 1998-02-17 1999-12-14 Ligand Pharmaceuticals Incorporated Process for the preparation of 1,2-dihydroquinolines
JP2002514616A (en) 1998-05-11 2002-05-21 ノボ ノルディスク アクティーゼルスカブ New compounds, their production and use
US6093826A (en) * 1998-06-08 2000-07-25 Ligand Pharmaceuticals Incorporated Process for the preparation of C(5)-substituted 1,2-dihydro-5H-chromeno[3,4-f] quinolines
GB9819019D0 (en) * 1998-09-01 1998-10-28 Cerebrus Ltd Chemical compounds II
US6255324B1 (en) * 1998-11-25 2001-07-03 Ned D. Heindel Amino-and mercurio-substituted 4′,5'-dihydropsoralens and therapeutical uses thereof
US6358948B1 (en) 1999-05-04 2002-03-19 American Home Products Corporation Quinazolinone and benzoxazine derivatives as progesterone receptor modulators
AU6941200A (en) 1999-08-27 2001-03-26 Ligand Pharmaceuticals Incorporated 8-substituted-6-trifluoromethyl-9-pyrido(3,2-g)quinoline compounds as androgen receptor modulators
US6566372B1 (en) 1999-08-27 2003-05-20 Ligand Pharmaceuticals Incorporated Bicyclic androgen and progesterone receptor modulator compounds and methods
CZ2002711A3 (en) 1999-08-27 2003-11-12 Ligand Pharmaceuticals Incorporated Androgenic receptor modulators, process of their preparation and their use
US6172241B1 (en) * 1999-10-15 2001-01-09 Ligand Pharmaceuticals Incorporated Process for the preparation of 1,2-dihydroquinolines
KR100397950B1 (en) * 2000-01-24 2003-09-19 주식회사 겟웰바이오 Analgesic composition comprising decursinol or derivative thereof
CN1230418C (en) 2000-08-24 2005-12-07 田纳西大学研究公司 Selective androgen receptor modulators and methods of use thereof
US7214690B2 (en) * 2001-02-23 2007-05-08 Ligand Pharmaceuticals Incorporated Tricyclic quinolinone and tricyclic quinoline androgen receptor modulator compounds and methods
US7026484B2 (en) 2001-02-23 2006-04-11 Ligand Pharmaceuticals Incorporated Tricyclic androgen receptor modulator compounds and methods
EP1414795A4 (en) 2001-07-31 2006-03-01 Bristol Myers Squibb Co Bicyclic modulators of androgen receptor function
DE20301728U1 (en) 2002-10-11 2004-03-11 Ligand Pharmaceuticals, Inc., San Diego 5-substituted-7,9-difluoro-5H-chromeno (3,4-f) quinoline compounds as selective progesterone receptor modulator compounds
EP1558618A1 (en) 2002-10-11 2005-08-03 Ligand Pharmaceuticals, Inc. 5-(1 ,1 -CYCLOALKYL/ALKENYL)METHYLIDENE 1,2-DIHYDRO- 5H /-CHROMENO[3,4-f ] QUINOLINES AS SELECTIVE PROGESTERONE RECEPTOR MODULATOR COMPOUNDS
TW200410968A (en) 2002-10-11 2004-07-01 Ligand Pharm Inc 5-cycloalkenyl 5H-chromeno[3,4-f]quinoline derivatives as selective progesterone receptor modulator compounds
EP1567487A4 (en) 2002-11-15 2005-11-16 Bristol Myers Squibb Co Open chain prolyl urea-related modulators of androgen receptor function
EP1656142A4 (en) 2003-08-22 2011-06-22 Ligand Pharm Inc 6-cycloamino-2-quinolinone derivatives as androgen receptor modulator compounds
WO2005082909A1 (en) * 2004-02-25 2005-09-09 Ligand Pharmaceuticals Incorporated Glucocorticoid receptor modulator compounds and methods- utility
WO2005090282A1 (en) 2004-03-12 2005-09-29 Ligand Pharmaceuticals Incorporated Androgen receptor modulator compounds and methods
CA2598216C (en) * 2005-06-17 2014-04-08 Ligand Pharmaceuticals Incorporated Androgen receptor modulator compounds and methods
US20090227571A1 (en) * 2005-07-01 2009-09-10 Ligand Pharmaceuticals Incorporated Androgen Receptor Modulator Compounds and Methods
US20090203725A1 (en) * 2005-12-21 2009-08-13 Cornelis Arjan Van Oeveren Androgen Receptor Modulator Compounds and Methods
CA2709677C (en) 2007-12-21 2017-03-14 Lin Zhi Selective androgen receptor modulators (sarms) and uses thereof

Also Published As

Publication number Publication date
CN101215286A (en) 2008-07-09
US20060128740A1 (en) 2006-06-15
JP2004524309A (en) 2004-08-12
JP2013040197A (en) 2013-02-28
US20020183346A1 (en) 2002-12-05
CA2434299A1 (en) 2002-08-29
US7727980B2 (en) 2010-06-01
US20100210678A1 (en) 2010-08-19
CN1492869A (en) 2004-04-28
JP2009161550A (en) 2009-07-23
JP4578053B2 (en) 2010-11-10
EP1363909B1 (en) 2016-10-12
MXPA03007421A (en) 2003-12-04
CA2434299C (en) 2011-01-25
EP1363909A2 (en) 2003-11-26
WO2002066475A2 (en) 2002-08-29
US20070293528A9 (en) 2007-12-20
AU2002236114A1 (en) 2002-09-04
WO2002066475A3 (en) 2003-01-23
US7026484B2 (en) 2006-04-11
CN100590124C (en) 2010-02-17

Similar Documents

Publication Publication Date Title
BR0207549A (en) Androgen receptor modulating tricyclic compounds and methods
BR0113930A (en) Heterocyclic Chemokine Receptor-Binding Compounds
BR0115482A (en) Improved sacralose composition and process for its preparation
DE60325025D1 (en) MODULATORS OF THE VANILLOID RECEPTOR
HN1998000175A (en) IMIDAZOTRIAZININS
DE60213276D1 (en) 1,2,4-thiadiazolium compounds as melanocortinreceptor modulators
ATE550688T1 (en) MICRO LIGHT MODULATOR ARRANGEMENT
DK1527035T3 (en) Continuous process for the alkylation of hydrocarbons
YU75601A (en) Process for the preparation of non-steroidal glucocorticid receptor modulators
BR9806852A (en) Vitronectin receptor antagonists
TR200000782T2 (en) Resorcinol derivatives.
FI20010335A0 (en) Arrangement for mixing the streams of the papermaking process
PT1189970E (en) CARBOXI-FUNCTIONAL ADDITIVE FOR THE CONDENSATION OF POLYAMIDES
BR0312378A (en) Cck-1 Receiver Modulators
ECSP034531A (en) SUBSTITUTED DERIVATIVES OF C-CICLOHEXILMETILAMINA
BR0213481A (en) Probes
BR0007922A (en) Calcilic compounds
DE60201256D1 (en) ELECTROOPTIC WAVEWAVE MODULATOR
DE60110517D1 (en) Light-controlled light modulator
BR0307978A (en) Bleach composition
ATE274417T1 (en) FIXING DEVICE
PT1339703E (en) PROCESS FOR THE PREPARATION OF PACLITAXEL
ATE304995T1 (en) MIXTURE CONTAINING BISPHENOL A
BR9815004A (en) Stabilized fabric softening compositions.
BR0315508A (en) Process for preparing pyrazole compounds

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B11D Dismissal acc. art. 38, par 2 of ipl - failure to pay fee after grant in time